Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of around 15 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB HY 2020 Consensus 

In € million HY 2020E
Average
HY 2020E
Median
P&L Consensus     
Revenue 2,471 2,487
REBIT 557 555
REBITDA  736 716
Net Profit  (after minorities) 408 428
Core EPS (€) 2.49 2.45
Product Sales Consensus     
Cimzia  852  844
Vimpat 684  681
Keppra 356  355 
Neupro 146  152 
Briviact 137  138 
Evenity (global, non-risk adj.) 184   178
Nayzilam 8

 

UCB FY Consensus Product Sales Estimates (Average)

In € million 2019a 2020e 2021e 2022e  2023e  2024e  2025e
Core Products              
Cimzia 1,712 1,837 1,919 1,966 1,943 1,783 1,531
Vimpat 1,322 1,471 1,582 1,431 962 769 642
Keppra  770 726 675 613 565 522 482
Briviact 221 294 366 431 492 546 585
Neupro 319 300 266 217 182 156 131
Potential new Product Launches
(global sales, non-risk adj.)
             
Evenity (romosozumab)   409  580  726  859 986  1,081
Midazolam nasal spray   18 38  57  77  92  102
Bimekizumab   102  337  616  914   1,230
Rozanolixizumab (Rozimab/Roza)   39  100 209  336
Padsevonil   3 24  49 74
Anti-Tau    0  0  0 83 191
Zilucoplan   0 0 59 159 276 417

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2019a 2020e 2021e 2022e  2023e
Net Sales  4,680 4,985 5,316 5,456 5,328
Revenue  4,913 5,197 5,518 5,655 5,519
Recurring EBIT 1,118  1,087 1,279 1,409 1,382
Recurring EBITDA 1,431  1,429 1,630 1,760 1,737
Net Profit*  792 763 928 1,044 1,033
Core EPS (€) 5.20  4.87 5.74 6.34 6.33

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2019a 2020e 2021e 2022e  2023e  2024e  2025e
Core Products              
Cimzia 1,712 1,850 1,916 2,006 1,971 1,854 1,554
Vimpat 1,322 1,449 1,553 1,454 956 750 588
Keppra 770 721 671 620 560 515 482
Briviact 221 296 365 428 483 532 581
Neupro 319 307 280 213 191 156 115
Potential new Product Launches
(global sales, non-risk adj.)
             
Evenity (romosozumab)   408 589 709 837 961 1,052 
Midazolam nasal spray   18 40  60  80  100 112
Bimekizumab   100  350 634  968  1,218 
Rozanolixizumab (Rozimab/Roza)   24 92 237  254
Padsevonil   0 0 0 0
Anti-Tau    0 100  238 
Zilucoplan   0 0 61 206 279 400

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2019a 2020e 2021e 2022e  2023e
Net Sales  4,680 4,970 5,336  5,463  5,343
Revenue  4,913 5,200 5,536 5,703 5,516
Recurring EBIT 1,118  1,085 1,303 1,440 1,450
Recurring EBITDA  1,431 1,424 1,629 1,768 1,787
Net Profit*  792  764 947 1,082 1,108
Core EPS (€) 5.20 4.91 5.85 6.50
6.59

*attributable to UCB shareholders

Downloads:
UCB HY 2020 & FY Consensus (Excel)
UCB HY 2020 Consensus (PDF)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 10 July, 2020



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.